W. Wu

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Wei Li, B. Xu, M. Robson, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

B. Xu, M. Robson, N. Tung, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).

R. Gelber, A. Tutt, J. Garber, 2015 .

OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).

M. Robson, Bing-he Xu, N. Tung, 2017 .

Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD

M. Robson, Bing-he Xu, N. Tung, 2018 .

Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.

J. Barrett, D. Hodgson, E. Harrington, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

CircRNA ANXA2 Promotes Lung Cancer Proliferation and Metastasis by Upregulating PDPK1 Expression

Xiaorui Shi, W. Wu, Bin Yuan, 2021, Journal of oncology.